MarketPulse

institutional investor

8 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Fund Sells $4.7M in Bread Financial Despite Stock Surge, Strong Earnings

Brooktree Capital Management sold $4.68M in BFH shares amid 76.5% YoY surge. Sale appears routine despite strong Q1 earnings and improving metrics.
IBKRBFHBFHpARMNIearnings growthshare buyback
The Motley FoolThe Motley Fool··Andy Gould

AXXCESS Exits $60M VTC Position: Strategic Rebalancing or Bond Market Signal?

AXXCESS Wealth Management exits entire $60M VTC stake; maintains corporate bond exposure through other holdings, suggesting strategic consolidation rather than sector retreat.
AGGVTCfixed incomeinterest rates
The Motley FoolThe Motley Fool··Jonathan Ponciano

Invera Wealth Cuts $2.8M ESG ETF Position as USXF Soars 42% Annually

Invera Wealth Advisors cut its $USXF stake by half in Q1 2026, selling $2.77 million despite the ESG fund's impressive 42% annual return.
USXFtechnology stocksmarket outperformance
BenzingaBenzinga··Lekha Gupta

Wearable Devices Raises $5M Via Warrant Deal as Stock Languishes 83% Below Year-Ago Levels

Wearable Devices ($WLDS) raises $5M through warrant agreement with institutional investor, exercising 2.9M shares at $1.73 each amid 83% annual decline.
WLDSWLDSWstock declinetechnical analysis
The Motley FoolThe Motley Fool··Andy Gould

Major Shareholder Trims $7.8M Harrow Stake, Signals Profit-Taking Over Retreat

Opaleye Management sold $7.8M in $HARR shares while retaining 10% stake, suggesting tactical rebalancing rather than loss of confidence in ophthalmic pharma company.
HROWearnings missportfolio rebalancing
The Motley FoolThe Motley Fool··Will Healy

Major Shareholder Cashes Out $19.4M in Hut 8 Stake Amid Valuation Concerns

Ardsley Advisory Partners sells 440,000 Hut 8 shares (55% stake) worth $19.4M in Q4 2025, citing concerns over 26x price-to-sales valuation despite strong growth.
LLYAVGOHUTFSLRLITE+1cryptocurrencydata centers
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Investor Trims $104M Nuvalent Stake as Cancer Drug Developer Surges 30%

Vestal Point Capital sold $103.93M in Nuvalent shares, reducing exposure despite company's 30% rally and $1.4B cash position awaiting 2026 FDA decisions.
ABBVNUVLTERNBMRNFDA approvalbiotech
The Motley FoolThe Motley Fool··Lawrence Rothman, Cfa

Irenic Capital Significantly Trims Papa John's Stake Amid Market Underperformance

Irenic Capital divests 70% of Papa John's stake due to underperformance, with stock down 30.7% over past year amid broader QSR sector challenges.
ITGRALKTPZZASHCTBPHsame-store sales declineunderperformance